About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 390563, 7 pages
http://dx.doi.org/10.1155/2013/390563
Clinical Study

Assessment of T Regulatory Cells and Expanded Profiling of Autoantibodies May Offer Novel Biomarkers for the Clinical Management of Systemic Sclerosis and Undifferentiated Connective Tissue Disease

1Clinical Pathology and Microbiology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy
2Clinical Dermatology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy
3Biostatistic Unit, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy

Received 28 January 2013; Revised 21 March 2013; Accepted 11 April 2013

Academic Editor: Nicolaus Kroger

Copyright © 2013 Paola Cordiali-Fei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gabrielli, E. V. Avvedimento, and T. Krieg, “Mechanisms of disease: scleroderma,” The New England Journal of Medicine, vol. 360, no. 19, pp. 1989–2003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Hachulla and D. Launay, “Diagnosis and classification of systemic sclerosis,” Clinical Reviews in Allergy and Immunology, vol. 40, no. 2, pp. 78–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Carwile LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Scopus
  4. Y. Hamaguchi, “Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis,” Journal of Dermatology, vol. 37, no. 1, pp. 42–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, “Preliminary criteria for the classification of systemic sclerosis (scleroderma),” Arthritis & Rheumatism, vol. 23, no. 5, pp. 581–590, 1980. View at Scopus
  6. O. Nadashkevich, P. Davis, and M. J. Fritzler, “A proposal of criteria for the classification of systemic sclerosis,” Medical Science Monitor, vol. 10, no. 11, pp. CR615–CR621, 2004. View at Scopus
  7. M. Mosca, C. Tani, R. Talarico, and S. Bombardieri, “Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases,” Autoimmunity Reviews, vol. 10, no. 5, pp. 256–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Mosca, C. Tani, and S. Bombardieri, “Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology,” Best Practice and Research, vol. 21, no. 6, pp. 1011–1023, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Gabrielli, S. Svegliati, G. Moroncini, and E. V. Avvedimento, “Pathogenic autoantibodies in systemic sclerosis,” Current Opinion in Immunology, vol. 19, no. 6, pp. 640–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Kuwana, J. Kaburaki, T. Mimori, Y. Kawakami, and T. Tojo, “Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis 2000,” Arthritis & Rheumatism, vol. 43, no. 5, pp. 1074–1084, 2000.
  11. T. Y. T. Lu, K. P. Ng, G. Cambridge et al., “A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients,” Arthritis Care and Research, vol. 61, no. 4, pp. 482–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Neubert, S. Meister, K. Moser et al., “The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis,” Nature Medicine, vol. 14, no. 7, pp. 748–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, “FOXP3 + regulatory T cells in the human immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 490–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Fujio, T. Okamura, S. Sumitomo, and K. Yamamoto, “Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity,” Annals of the Rheumatic Diseases, vol. 72, pp. ii85–ii89, 2013. View at Publisher · View at Google Scholar
  15. S. Huber, N. Gagliani, E. Esplugues et al., “Th17 cells express IL-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner,” Immunity, vol. 34, no. 4, pp. 554–565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Chaudhry, D. Rudra, P. Treuting et al., “CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner,” Science, vol. 326, no. 5955, pp. 986–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Cederbom, H. Hall, and F. Ivars, “CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells,” European Journal of Immunology, vol. 30, pp. 1538–1543, 2000.
  18. S. Mehra, J. Walker, K. Patterson, and M. J. Fritzler, “Autoantibodies in systemic sclerosis,” Autoimmunity Reviews, vol. 12, pp. 340–354, 2013.
  19. D. E. Furst, P. J. Clements, V. D. Steen et al., “The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis,” Journal of Rheumatology, vol. 25, no. 1, pp. 84–88, 1998. View at Scopus
  20. E. C. LeRoy and T. A. Medsger Jr., “Criteria for the classification of early systemic sclerosis,” Journal of Rheumatology, vol. 28, no. 7, pp. 1573–1576, 2001. View at Scopus
  21. A. Balbir-Gurman and Y. Braun-Moscovici, “Scleroderma overlap syndrome,” Israel Medical Association Journal, vol. 13, no. 1, pp. 14–20, 2011. View at Scopus
  22. U. A. Walker, A. Tyndall, L. Czirják, et al., “Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database,” Annals of the Rheumatic Diseases, vol. 66, pp. 754–763, 2007.
  23. I. N. Targoff, A. E. Johnson, and F. W. Miller, “Antibody to signal recognition particle in polymyositis,” Arthritis & Rheumatism, vol. 33, no. 9, pp. 1361–1370, 1990. View at Scopus
  24. A. H. Kao, D. Lacomis, M. Lucas, N. Fertig, and C. V. Oddis, “Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy,” Arthritis & Rheumatism, vol. 50, no. 1, pp. 209–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. M. C. Tamby, Y. Chanseaud, L. Guillevin, and L. Mouthon, “New insights into the pathogenesis of systemic sclerosis,” Autoimmunity Reviews, vol. 2, no. 3, pp. 152–157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Mimura, H. Ihn, M. Jinnin, Y. Asano, K. Yamane, and K. Tamaki, “Clinical and laboratory features of scleroderma patients developing skeletal myopathy,” Clinical Rheumatology, vol. 24, no. 2, pp. 99–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Ranque, F. J. Authier, V. Le-Guern et al., “A descriptive and prognostic study of systemic sclerosis-associated myopathies,” Annals of the Rheumatic Diseases, vol. 68, no. 9, pp. 1474–1477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Partovi, A. C. Schulte, M. Aschwanden, et al., “Impaired skeletal muscle microcirculation in systemic sclerosis,” Arthritis Research & Therapy, vol. 14, no. 5, article R209, 2012.
  29. E. Katzap, M. L. Barilla-Labarca, and G. Marder, “Antisynthetase syndrome,” Current Rheumatology Reports, vol. 13, no. 3, pp. 175–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Kalluri, S. A. Sahn, C. V. Oddis et al., “Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature,” Chest, vol. 135, no. 6, pp. 1550–1556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. R. W. Koschik, N. Fertig, M. R. Lucas, R. T. Domsic, and T. A. Medsger Jr., “Anti-PM-Scl antibody in patients with systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 30, no. 2, supplement 71, pp. s12–s16, 2012.
  32. J. L. Sargent and M. L. Whitfield, “Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling,” Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 463–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Wildin, S. Smyk-Pearson, and A. H. Filipovich, “Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome,” Journal of Medical Genetics, vol. 39, no. 8, pp. 537–545, 2002. View at Scopus
  34. E. Antiga, P. Quaglino, S. Bellandi et al., “Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea,” British Journal of Dermatology, vol. 162, no. 5, pp. 1056–1063, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. R. Jocea, M. van Amelsfort, G. J. Walter, and L. S. Taams, “CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases,” Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 499–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Fenoglio, F. Battaglia, A. Parodi et al., “Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis,” Clinical Immunology, vol. 139, no. 3, pp. 249–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Giovannetti, E. Rosato, C. Renzi et al., “Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes,” Clinical Immunology, vol. 137, no. 1, pp. 122–133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Slobodin, M. S. Ahmad, I. Rosner et al., “Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity,” Cellular Immunology, vol. 261, no. 2, pp. 77–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. T. R. D. J. Radstake, L. van Bon, J. Broen et al., “Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression,” PLoS ONE, vol. 4, no. 6, Article ID e5981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. R. Katsumoto, M. L. Whitfield, and M. K. Connolly, “The pathogenesis of systemic sclerosis,” Annual Review of Pathology, vol. 6, pp. 509–537, 2011.
  41. M. Hasegawa and K. Takehara, “Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines,” Seminars in Arthritis and Rheumatism, vol. 42, pp. 281–296, 2012.